Expert Interview
Evaluating the 52-week data from the Phase 2b VOYAGE Study of VK2809 in patients with NASH from the 75th Liver Meeting 2024
Ticker(s): VKTXInstitution: Penn State
- Transplant Hematologist & Assistant Professor Medicine, Gastroenterology & Hepatology at Penn State.
- 60% clinical research largely focusing on NASH; hepatology group sees >750 patients with NAFLD/NASH a year of which he manages 25%.
- Lectures nationally on NASH and hi research in this field; and familiar with the MGL-3196 36 Week Data and VK2809.
1. Could you share details about your professional background and clinical practice, and how do you view the current state and future of NASH treatment based on your experience?
Added By: slingshot_insights2. How is Rezdiffra being integrated with other therapies like GLP-1 agonists, and do you prescribe GLP-1 agonists or refer patients to endocrinologists?
3. Is there a need for NASH-specific drugs, or could GLP-1 agonists and weight loss medications suffice, and how does the efficacy of Rezdiffra compare to other treatments like VK2809 and semaglutide?
Added By: slingshot_insights4. What is your impression of the VOYAGE study’s data, including the high placebo response rates, and does the safety and tolerability profile of VK2809 differentiate it from other options?
Added By: slingshot_insights5. How do you view the potential of combination therapies like VK2735’s dual GLP-1/GIP agonist approach, and what would be the impact of oral formulations versus injectable options on patient adherence?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
